-
Rivaroxaban, sold
under the
brand name
Xarelto among others, is an
anticoagulant medication (blood thinner) used to
treat and
prevent blood clots. Specifically...
- antagonists. Reynolds,
Matthew R. (February 2013). "Discontinuation of
Rivaroxaban:
Filling in the Gaps" (editorial comment). J. Am. Coll. Cardiol. 61 (6):...
-
brand name
Andexxa among others, is an
antidote for the
medications rivaroxaban and apixaban, when
reversal of
anticoagulation is
needed due to uncontrolled...
-
gross revenue. In 2019,
identified "key growth"
products were
Xarelto (
rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and...
-
include direct thrombin inhibitor (dabigatran) and
factor Xa
inhibitor (
rivaroxaban, apixaban,
betrixaban and edoxaban), and they have been
shown to be as...
- hemorrhage, and all-cause
mortality compared with dabigatran, edoxaban, and
rivaroxaban.
Dabigatran is
contraindicated in
patients who have
active pathological...
-
anticoagulant (anti-blood clotting) drugs,
including factor Xa
inhibitors (
rivaroxaban,
apixaban and edoxaban), dabigatran, and
heparins (including fondaparinux...
- failure.
Apixaban and
other anticoagulants (dabigatran,
edoxaban and
rivaroxaban)
appear equally effective as
warfarin in
preventing non-hemorrhagic stroke...
- one of the
direct oral
anticoagulant drugs (DOACs, e.g. dabigatran,
rivaroxaban, edoxaban, or apixaban) is recommended. If the
patient is 'low risk'...
- B01AE07
Dabigatran etexilate B01AF01
Rivaroxaban B01AF02
Apixaban B01AF03
Edoxaban B01AF04
Betrixaban B01AF51
Rivaroxaban and
acetylsalicylic acid B01AX01...
